Horizon Therapeutics Public Limited Co (fka HZNP)

[surf1944]

8:03AM Horizon Pharma announces receipt of fifth US patent allowance for DUEXIS (HZNP) 2.44 : Co announces it has received a Notice of Allowance (NOA) from the US Patent and Trademark Office (USPTO) for Patent Application Serial No. 13/620141 entitled "Stable Compositions of Famotidine and Ibuprofen" with claims that cover DUEXIS (ibuprofen and famotidine) tablets. DUEXIS is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers. The Notice of Allowance concludes the substantive examination of this US patent application and will result in the issuance of a US patent after administrative processes are completed. The US patent scheduled to issue from this application will expire in 2028.